Q-omics provides the consensus-scored TK2 profile across patient tissues and cancer cell-line models. TK2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TK2 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, TK2 RNA expression shows 19,222 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KICH, and UVM as cancer lineages where TK2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TK2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TK2 survival associations across molecular data types. TK2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TK2 RNA expression–survival associations across cancer types. High TK2 expression shows unfavorable associations in LUSC and BLCA, but favorable associations in KIRP, BRCA, COAD and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TK2 RNA expression.
This table summarizes TK2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TK2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TK2 shows lower tumor expression in KICH, LUSC, UCEC and BRCA and higher tumor expression in STAD and KIRP. The KICH box plot shows higher TK2 RNA expression in normal versus tumor tissue (log2 FC = −0.495, t-test p < 0.001).
This table shows molecular features associated with TK2 in patient tissues and cancer cell lines. In patient samples, TK2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TK2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
